Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company focuses on developing novel medicines that target key molecular pathways in cancers, with the goal of extending and enhancing the lives of patients. Its portfolio comprises of two oncology franchises focused on kinase inhibition and proteasome inhibition, and includes approved therapies in solid and hematological malignances. The company was founded by Frank McCormick in February 1992 and is headquartered in South San Francisco, CA.